LL-37 vs TB-500
A side-by-side research comparison of LL-37 and TB-500 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LL-37 | TB-500 |
|---|---|---|
| Full name | Cathelicidin Antimicrobial Peptide LL-37 | Thymosin Beta-4 (Synthetic) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. | Upregulates actin production to promote cell migration and proliferation, enhances angiogenesis, and reduces pro-inflammatory cytokines. |
| Molecular weight | 4493.33 Da | 4921 Da |
| Half-life | ~4-6 hours | ~6 hours |
| Bioavailability | Variable by route; topical and injectable | ~95% via subcutaneous injection |
| Typical dose | 50-100 mcg | 2-5 mg per dose |
| Frequency | Daily | Loading: 2x/week · Maintenance: 1x/week |
| Route | Topical or subcutaneous injection | Subcutaneous injection |
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
TB-500 reported benefits
- Enhanced wound healing
- Reduced inflammation
- Improved flexibility
- Cardiac tissue repair
- Hair regrowth support
Related comparisons
Research and educational reference only. Not medical advice.